Immunology Market 2022 Forecast Report Available Now at Radiant Insights, Inc

Summary

Immune-mediated inflammatory diseases are a very common set of chronic disorders that affect 5–7% of western populations. Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologically linked, being characterized by dysregulation of immune pathways and an inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, a highly genericized class of systemic small-molecule-based agents, are used in the first-line treatment of these diseases. These are supplemented in many cases by shorter-term glucocorticoid therapy, another class of highly genericized systemic agents.

However, as these therapies often fail to elicit an adequate long-term response, a large second-line therapy segment has emerged in these markets, beginning with the approval of Remicade (infliximab) and Enbrel (etanercept) in 1998. This segment consists largely of premium systemic monoclonal Antibodies (mAbs), which are highly commercially successful due to their widespread usage and high cost. Although the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience continued growth.

Read Complete Report with TOC @ http://www.radiantinsights.com/research/global-immunology-market-to-2022

Scope

Although the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience continued growth, from $61.5 billion in 2015 to $74.2 billion in 2022, at a compound annual growth rate of 2.71%.

• What factors are driving the market growth?
• How can the factors limiting growth be overcome?

There is a very large pharmaceutical pipeline for immunology, consisting of 1,838 products in active development. However, the commercial performance of the products in the late-stage pipeline is expected to be moderate.

• What gaps in the market are being addressed by the most promising of these late-stage pipeline products?
• How does the composition of the pipeline compare with that of the existing market?

Read Sample report of this Category: http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare

Several key commercially successful products, including Humira (adalimumab) and Remicade, are due to lose patent protection in the forecast period.

• How will this affect their revenues in this period?
• How are their manufacturers, AbbVie and Johnson & Johnson, responding to this?

The key players in the market, all of which are among the top 20 pharmaceutical companies, are expected to maintain their market lead throughout the forecast period.

• What is driving this continued market dominance?
• Who will the new market players be?

Reasons to buy

This report will allow you to -

• Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis
• Visualize the composition of the immunology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
• Analyze the immunology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
• Understand the growth in patient epidemiology and market revenues for the immunology market globally and across the key players and product types
• Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various immunological disorders
• Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For More Information, Visit Radiant Insights

Contact:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Email: sales@radiantinsights.com

Blog URL: http://www.radiantinsightsinc.blogspot.com

About Radiant Insights Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements.